Anti-MSR1 antibodies and methods of use thereof

US11377502B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Jesper Gromada · Scarsdale, US
• Viktoria Gusarova · Pleasantville, US
• Amy Han · Hockessin, US
• Sokol Haxhinasto · Brookfield, US
• Christos Kyratsous · Dobbs Ferry, US
• Andrew J. Murphy · Croton-on-Hudson, US
• Thomas Nittoli · Pearl River, US
• William Olson · Ossining, US
• Matthew Sleeman · Pidley, GB
• Anna Zumsteg · Elmsford, US

Key dates

• Filing date: May 8, 2019
• Grant date: Jul 5, 2022
• Expiry date: Apr 5, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.